TransCode Therapeutics effects 1-for-20 reverse stock split to meet Nasdaq bid price rule

Transcode Therapeutics, Inc.

1-for-20 reverse split effective 4:05 pm ET May 22, 2023; trading on split-adjusted basis begins May 23.
Pre-split outstanding shares ~16,998,534 reduced to ~849,926 post-split shares.
Reverse split intended to satisfy Nasdaq minimum $1.00 bid price continued listing requirement.
No fractional shares issued; cash paid for fractional interests based on May 22 closing price.
Trading symbol RNAZ unchanged; new CUSIP 89357L 204; Vstock Transfer LLC acting as exchange agent.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Transcode Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock (effective 2023-05-22).

Change: charter amendment
Effective: 2023-05-22

Exact text from the filing

On May 19, 2023, TransCode Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), as of 4:05 p.m. Eastern Time on May 22, 2023 (the “Effective Time”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-062930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.